113 related articles for article (PubMed ID: 29932782)
1. PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.
Podszywalow-Bartnicka P; Maifrede S; Le BV; Nieborowska-Skorska M; Piwocka K; Skorski T
Leuk Lymphoma; 2019 Jan; 60(1):262-264. PubMed ID: 29932782
[No Abstract] [Full Text] [Related]
2. Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.
Li W; Ding Q; Ding Y; Lu L; Wang X; Zhang Y; Zhang X; Guo Q; Zhao L
Mol Carcinog; 2017 Mar; 56(3):863-876. PubMed ID: 27533597
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
[TBL] [Abstract][Full Text] [Related]
4. Editorial: CML HSCs: Are the True Enemies for the Patient?
Mancini M
Curr Drug Targets; 2017; 18(4):376. PubMed ID: 28264644
[No Abstract] [Full Text] [Related]
5. BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
Xu X; Zhang X; Liu Y; Yang L; Huang S; Lu L; Wang S; Guo Q; Zhao L
Oncotarget; 2016 Apr; 7(17):24436-54. PubMed ID: 27027438
[TBL] [Abstract][Full Text] [Related]
6. Biology: Three known unknowns.
Bourzac K
Nature; 2014 May; 509(7502):S69-71. PubMed ID: 24870828
[No Abstract] [Full Text] [Related]
7. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
8. Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells.
Than H; Pomicter AD; Yan D; Beaver LP; Eiring AM; Heaton WL; Senina A; Clair PM; Shacham S; Mason CC; Hare TO; Deininger MW
Leukemia; 2020 Jun; 34(6):1679-1683. PubMed ID: 31980730
[No Abstract] [Full Text] [Related]
9. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q
Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204
[TBL] [Abstract][Full Text] [Related]
10. Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia.
Guo Y; Li Y; Shan Q; He G; Lin J; Gong Y
Int J Biochem Cell Biol; 2015 Aug; 65():1-11. PubMed ID: 25979368
[TBL] [Abstract][Full Text] [Related]
11. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
[TBL] [Abstract][Full Text] [Related]
12. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
13. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
[TBL] [Abstract][Full Text] [Related]
14. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
16. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
[TBL] [Abstract][Full Text] [Related]
17. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.
Nair RR; Tolentino JH; Argilagos RF; Zhang L; Pinilla-Ibarz J; Hazlehurst LA
Leuk Res; 2012 Jun; 36(6):756-63. PubMed ID: 22209738
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W
J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
Zhang H; Liang Z; Hu Y; Wang X; Wang B; Huang H
Leuk Lymphoma; 2018 Dec; 59(12):3018-3019. PubMed ID: 29616854
[No Abstract] [Full Text] [Related]
[Next] [New Search]
